About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Plasma Exchange as Rescue Therapy for Patient with Poorly Responsive Guillain-Barre syndrome
Dawlat Sany1, Anandi Damodaran2, Devdutt Kotekar2
1Consultant Internal Medicine and Nephrology, Kalba Hospital, Sharjah, EHS. 2Consultant Neurologist, Kuwait Hospital, Sharjah, EHS, United Arab Emirates.
Corresponding Author:
Dr. Dawlat Hussein Sany
Email: dawlat.hussein@ehs.gov.ae
Received: 18-APR-2023 Accepted: 23-JUN-2023 Published Online: 25-JUL-2023
DOI: http://dx.doi.org/10.17659/01.2023.0020
Abstract
Background: Intravenous immunoglobulin (IVIg) has traditionally served as the primary treatment for Guillain-Barré syndrome (GBS), reserving plasmapheresis for severe cases or as an adjunctive therapy with uncertain outcomes. Currently, there is no robust recommendation supporting the utility of therapeutic plasma exchange (TPE) following IVIg treatment failure. Case Report: In this report, we present a case of severe GBS accompanied by respiratory failure necessitating mechanical ventilation. Nerve conduction studies and electromyography (EMG) findings indicated a profound hyperacute motor sensory axonal neuropathy phenotype of GBS. Despite an initial course of IVIg at a dosage of 0.4 g/kg administered over five consecutive days, the patient exhibited no improvement. However, a notable turnaround in the patient's condition was observed following TPE. Conclusion: This case report underscores the potential benefit of TPE as a viable treatment option for select patients who fail to respond to immunoglobulin therapy, shedding light on its effectiveness in such challenging cases of GBS.
Keywords : Guillain-Barre Syndrome, Intravenous immunoglobulins, Plasmapheresis, Respiratory Failure, Sensory Neuropathy.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports

abortion pill online

Secure abortion pill tablets. There he could simply order pill for abortion online generic.There we could simply order generic site.
Last updated on Jul 03, 2024